Genea Biocells is a neuromuscular disease-focused preclinical-stage company using proprietary human pluripotent stem cell technologies. We leverage our expertise in human pluripotent stem cell derivation, banking and unique skeletal muscle differentiation for disease modeling, assay development and screening. We provide services and reagents to foster partnerships for biomedical research and drug development.
Genea Biocells has one of the world’s largest banks of pluripotent human embryonic stem cells and developed the world’s first consistent, scalable and high-yield differentiation process for functional skeletal muscle cells.
Genea Biocells is based in San Diego, California and is part of the Australian Genea group, a public, unlisted company that has been operating world leading IVF clinics since 1985. The company has been supplying commercial stem cell solutions for 10 years, drawing on an almost 30 year research heritage within Genea.